Intra Medica Exim Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 33 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.56 M
- Revenue Growth 109.82%
- Profit Growth 306.46%
- Ebitda -44.79%
- Net Worth 135.71%
- Total Assets 46.89%
About Intra Medica Exim
Intra Medica Exim Private Limited (IMEPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 November 1991 and has a history of 33 years and three months. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.56 M.
Vivek Mago and Shilpa Mago serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74899DL1991PTC046415
- Company No.
046415
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 1991
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Intra Medica Exim?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Mago  | Director | 15-Nov-1991 | Current |
| Shilpa Mago | Director | 09-Feb-2009 | Current |
Financial Performance of Intra Medica Exim.
Intra Medica Exim Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 109.82% increase. The company also saw a substantial improvement in profitability, with a 306.46% increase in profit. The company's net worth Soared by an impressive increase of 135.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intra Medica Exim?
In 2017, Intra Medica Exim had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kidney Care Fluids Private LimitedVivek Mago and Shilpa Mago are mutual person
Charges (Loans)
₹4.56 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Maharashtra : 0.25 Cr
- Hdfc Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Mar 2022 | Hdfc Bank Limited | ₹2.06 M | Open |
| 18 Jan 2005 | Bank Of Maharashtra | ₹2.00 M | Open |
| 09 Jun 2001 | Bank Of Maharashtra | ₹0.50 M | Open |
How Many Employees Work at Intra Medica Exim?
Unlock and access historical data on people associated with Intra Medica Exim, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intra Medica Exim, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intra Medica Exim's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
